The trailblazing study will use the data from up to 1.4million NHS patients to test whether its shingles vaccine reduces the ...

We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

On March 10, Dr. Nisha Acharya got a letter from the National Institutes of Health terminating her grant to study the safety and effectiveness of a vaccine recommended for all adults 50 and older in ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

Auckland deputy mayor Desley Simpson recently suffered from a painful shingles infection she likened to having "a hedgehog ...

Shingles can be an extremely painful condition and complications can be long-lasting, particularly for older people and those ...

The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis ...

Shingles can be an extremely painful condition and complications can be long-lasting, particularly for older people and those ...

Multinational companies in China’s vaccine market face headwinds amid an anti-corruption crackdown and rising competition.

GSK, led by boss Emma Walmsley (pictured), is using the data of 1.4m adults aged 65 and 66 to examine the impact of its ...

The study will analyse electronic health records of 65- and 66-year olds from the UK’s National Health Service (NHS).